Often recorded adverse reactions from the skin.
Classification of incidence of adverse reactions:
very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1000, <1/100); rarely (≥1 / 10000, <1/1000); very rarely (<1/10000), including individual messages and reactions with unknown frequency (can not be calculated based on available data). Immune system disorders:
Very rarely: hypersensitivity (including urticaria), angioedema.
Infectious and parasitic diseases:
Very rarely: pustular rash.
Disturbances from the respiratory system, chest and mediastinal organs:
Very rarely: bronchial asthma.
Disturbances from the skin and subcutaneous tissues:
Often: rash, eczema, erythema, dermatitis (including contact dermatitis), itching *;
Rarely: bullous dermatitis;
Very rarely: the reaction of photosensitivity;
Unknown: reaction at the application site, dry skin, burning sensation.
* 3d in the clinical trial was recorded at 0.9%, 236 patients with ankle sprain were treated with 4-5 doses of Voltaren® spray 3 times a day (120 patients) or placebo (116 patients) on for 14 days.
The frequency of undesirable effects can be reduced by applying the minimum effective dose over the period of the least possible duration. The total single dose of the drug should not exceed 1.0 g (equivalent to 5 doses (pressures)) of the spray.
However, during long-term treatment (more than three weeks) and / or when applied to a large surface area (ie, more than 600 square centimeters of body surface area), there is the possibility of systemic adverse reactions.
There can develop such reactions as abdominal pain, indigestion, disorders of the stomach and kidneys.